Slate Medicines

Slate MedicinesSlate Medicines
SM

Slate Medicines

Advancing anti-PACAP therapies for the prevention of migraine and other headache disorders.

Website
DR 122024ActiveCambridge, United States
Rate
Advertise here

About

Slate Medicines is a biotechnology company focused on developing novel anti-PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) therapies for the prevention and treatment of migraine and other severe headache disorders. The company launched with a significant Series A financing to support its therapeutic pipeline.
Frequently asked

What does Slate Medicines do?

Slate Medicines is a biotechnology company focused on developing novel anti-PACAP (Pituitary Adenylate Cyclase-Activating Polypeptide) therapies for the prevention and treatment of migraine and other severe headache disorders. The company launched with a significant Series A financing to support its therapeutic pipeline.

What is Slate Medicines's revenue?

StartupHub estimates Slate Medicines's annual revenue at $18.0M (range $6.4M to $54.6M, 34% confidence), based on comparable companies in the sector.

What is Slate Medicines's valuation?

StartupHub estimates Slate Medicines's effective valuation at $496.6M (range $325.0M to $780.0M, 23% confidence), based on comparable companies in the sector.

How much funding has Slate Medicines raised?

Slate Medicines has raised a total of $130M in funding. The most recent round on record is Series A.

Where is Slate Medicines headquartered?

Slate Medicines is headquartered in Cambridge, Massachusetts, United States.

When was Slate Medicines founded?

Slate Medicines was founded in 2024.

What industry does Slate Medicines operate in?

Slate Medicines operates in Biotechnology, Pharmaceuticals, Therapeutics, Healthcare.

Comments

No comments yet. Be the first to share your take.